Radiation beads & immune drugs: new hope for tough liver cancer
NCT ID NCT06058663
Summary
This early-stage study is testing the safety of a three-part treatment for advanced bile duct cancer in the liver that cannot be removed by surgery. Doctors combine a targeted radiation treatment (Y90 radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) to see if they can better control the cancer. The trial will enroll about 16 patients to find the safest way to give this combination and see if it shows early signs of helping.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III INTRAHEPATIC CHOLANGIOCARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.